2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Pharmaceuticals - Wikipedia
Teva and Active Signs Agreement to Study By CIOReview Team
Active Biotech's partner Teva starts laquinimod clinical trial
Teva and Active Biotech Expand Investigational MS Treatment Program
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
CHMP says no to Laquinimod
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Teva - Smart Woman Securities
3 Reasons to Buy Teva Right Now - TheStreet
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva returns laquinimod global rights to Active Biotech
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Active Biotech provides update on laquinimod in Huntington's disease - Huntington's Disease News
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Active Biotech Pivots Away from MS and Huntington's Disease, Goes in New Direction | BioSpace
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
The top 10 leading biotech companies | biotechworldwide.net
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
PharmaShots | Incisive News in 3 Shots
